Instil Bio Q3 net loss per share narrows

Instil Bio

13/11/2025 12:09

Overview

Instil Bio Q3 net loss per share improves to $2.01 from $3.54 yr/yr

Company's cash and investments fall to $83.4 mln from $115.1 mln at end of 2024

Research and development expenses rise to $9.1 mln from $0.6 mln yr/yr

Outlook

Instil expects cash resources to fund operations beyond 2026

Result Drivers

R&D EXPENSES - Research and development expenses increased to $9.1 mln from $0.6 mln yr/yr, reflecting investment in clinical trials

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Basic EPS
-$2.01


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Instil Bio Inc is $88.00, about 83% above its November 12 closing price of $14.99

Press Release: ID:nGNXXMF26

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)